NL-OMON21108已完成不适用
Efficacy and safety of Mylotarg� (gemtuzumab ozogamicin) as salvage treatment in children with refractory or relapsed acute myeloid leukemia.
VUmc, Amsterdam0 个研究点目标入组 50 人开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 50
研究概览
简要总结
/A
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •1. Children with primary refractory or relapsed AML, who do not respond to treatment according to the Relapsed AML 2001/01 re-induction protocol, defined as an M3 marrow after 1 course of chemotherapy or no CR after 2 courses of treatment according to this protocol (either FLAG or FLAG/DNX);
- •2. Children who relapse after having achieved CR by treatment according to the Relapsed AML 2001/01 trial;
排除标准
- •1. Isolated extramedullary relapse;
- •2. Active, symptomatic CNS leukemia in case of combined relapse;
研究者
相似试验
已完成
2 期
Mylotarg and Ara-C in Untreated Patients Above 60 Years With AML and High-Risk MDSAcute Myeloid LeukemiaMyelodysplastic SyndromeNCT00195000Weill Medical College of Cornell University43
撤回
2 期
Gemtuzumab Ozogamicin in Treating Patients With Acute Myeloid LeukemiaAdult Acute Myeloid Leukemia With 11q23 (MLL) AbnormalitiesAdult Acute Myeloid Leukemia With Del(5q)Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)Adult Acute Promyelocytic Leukemia (M3)Recurrent Adult Acute Myeloid LeukemiaNCT01548911Wake Forest University Health Sciences
招募中
2 期
Study of the efficacy and safety of gemtuzumab ozogamicin treatment intervention with measurable residual disease as an index for AYA/adult acute myeloid leukemia with t(8;21) and inv(16)JPRN-jRCTs041200063Toshihiro Miyamoto117
Unknown
不适用
Retrospective Analysis of the Outcome of Patients With Relapsed/Refractory Acute Myeloid Leukemia Included in a Patient Named Program of Gemtuzumab Ozogamicin/Mylotarg®Leukemia, Myeloid, AcuteNCT03287128Versailles Hospital300
Approved For Marketing
不适用
Gemtuzumab Ozogamicin in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Acute Promyelocytic LeukemiaAdult Acute Myeloid Leukemia With 11q23 (MLL) AbnormalitiesAdult Acute Myeloid Leukemia With Del(5q)Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)Adult Acute Promyelocytic Leukemia (M3)Childhood Acute Promyelocytic Leukemia (M3)Recurrent Adult Acute Myeloid LeukemiaRecurrent Childhood Acute Myeloid LeukemiaNCT01869803Wake Forest University Health Sciences